Related Experiment Video
Updated: Feb 4, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Tofacitinib for the treatment of ulcerative colitis
Agnès Fernández-Clotet1, Jesús Castro-Poceiro1,2, Julián Panés1,2
1a Inflammatory Bowel Disease Group , Institut d'Investigacions Biomètiques August Pi I Sunyer (IDIBAPS) , Barcelona , Spain.
Introduction:
New generations of small molecules are being developed for the treatment of ulcerative colitis. Among them, tofatinib (a Janus kinase (JAK) inhibitor) has demonstrated efficacy for inducing and maintaining remission and achieving mucosal healing with a reasonable safety profile. Oral administration is attractive for patients and lack of immunogenicity represents an advantage over biologic drugs. Areas covered: This review discusses the molecular aspects of the JAK-STAT pathway; the mechanism of action of tofacitinib pertinent to ulcerative colitis and the evidence on the efficacy of tofacitinib for achieving clinically relevant outcomes, including clinical remission, mucosal healing, and normalization of quality of life, as well as safety aspects with special attention to adverse events related to the mode of action of the drug. Expert commentary: Tofacitinib will be the first drug on the class of JAK inhibitors to be available for treatment of ulcerative colitis. The efficacy of the drug, with a rapid onset of action even in cases of severe colitis, oral administration, and possibility to use the drug intermittently without generating immunogenicity, will bring about a redesign of current treatment paradigms for ulcerative colitis.
Insights
Tofacitinib, a Janus kinase (JAK) inhibitor, shows efficacy in treating ulcerative colitis by inducing remission and promoting healing. Its oral administration and lack of immunogenicity offer advantages over existing biologic drugs.
Area of Science:
- Gastroenterology
- Pharmacology
- Immunology
Background:
- Ulcerative colitis (UC) treatment is evolving with new small molecule therapies.
- Janus kinase (JAK) inhibitors represent a novel therapeutic class for UC.
- Tofacitinib targets the JAK-STAT pathway, crucial in inflammatory processes.
Purpose of the Study:
- To review the molecular mechanisms of the JAK-STAT pathway.
- To examine tofacitinib's action in ulcerative colitis.
- To evaluate the efficacy and safety of tofacitinib for UC treatment.
Main Methods:
- Literature review of studies on tofacitinib and ulcerative colitis.
- Analysis of clinical trial data regarding efficacy and safety.
- Discussion of the JAK-STAT pathway's role in UC pathogenesis.
Main Results:
- Tofacitinib demonstrates efficacy in inducing and maintaining remission in UC patients.
- Mucosal healing and quality of life improvements are observed with tofacitinib treatment.
- Tofacitinib presents a favorable safety profile with manageable adverse events.
Conclusions:
- Tofacitinib is poised to be the first JAK inhibitor approved for UC treatment.
- Its rapid onset, oral administration, and non-immunogenic profile offer significant advantages.
- Tofacitinib may reshape current treatment strategies for ulcerative colitis.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:28Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...